ReproNeuro™: Human iPS cell derived Neurons

Product Classification : hiPSC-NeuronsResearch Theme : Alzheimer's disease, Drug Effect Test, Pharmacological Effectiveness Test, Electrophysiology Testing, Parkinson's disease, Safety Test, Toxicology test

Neuro
summary

The world’s first Commercial Human iPSC derived Neurons

Features

 ・Stable supply of phenotypically normal human neuronal cells
 ・Recombinant and patient- derived Alzheimer Disease-model neurons available
 ・Suitable for neurotoxicity assays and drug screening
 ・Functionally active as determined by MEA and Ca2+– flux assays

The cells provided are immature neurons. When cultured in ReproNeuro Culture Medium or ReproNeuro MQ Medium, ReproNeuro™ cells will differentiate into a mixed population of brain-like neurons.


Overview

ReproNeuro™ is a cell product that will undergo final maturation into neuronal cells when cultured with your choice of recommended media for 7-14 days.

Recommended media:
 ・ReproNeuro Culture Medium (Cat. No. RCDN101)
 ・ReproNeuro MQ Medium (Cat. No. RCDN102)

βIII-tubulin

TH

Vglut1

GABA

βIII-tubulin

TH

Vglut1

GABA


≪Technical Data≫

Intracellular Ca2+ signaling imagine

The dynamic modulation of Ca2+ concentration in ReproNeuro™ differentiated neuronal cells can be observed with the application of a fluorescent calcium binding dye (Fluo-8). Glutamine derived induction of calcium flux was shown in nearly all of the applied neurons.

Before induction

After 100 μM Glutamine induction

βIII-tubulin

βIII-tubulin

Courtesy of Prof. Oka and Mr. Enya, Keio University

Dopamine release by dopaminergic neurons derived from ReproNeuro™

ReproNeuro™ cells derived from human iPS cells were first treated with high concentration Ca2+ (56 μM) to polarize the cells. After polarization, increased dopamine concentration in the culture medium was detected, indicating the functional capability of dopamine release in ReproNeuro™ cells.

Dopamine uptake by dopaminergic neurons derived from ReproNeuro™

ReproNeuro™ cells derived from human iPS cells were treated with DMSO or DAT (Dopamine Transporter) inhibitor (GBR12909, 20 μM). Dopamine uptake was measured by Neurotransmitter transporter uptake assay kit (Molecular Device). The fluorescence intensity in controls were decreased by DAT inhibitor treatment indicating a block of neurotransmitter transporter in ReproNeuro™.

Products

Catalog No. Product Price
RCDN001N ReproNeuro™
Contents: 3 x 106 cells/vial*
 * We guarantee recovery of 3 x 106 live cells. Delivered in frozen format. Enough for 1x96 well plate.
Contact us

Storage conditions: liquid nitrogen
This product only contains a frozen cell suspension. For cell culture and downstream experiments, media and reagents are required, see related products below.

Related Products

Neurons derived from Alzheimer’s disease patient reprogrammed iPS cells

Transgenic Alzheimer's disease model cells

Neurons derived from human iPS cells transfected with mutated presenilin1 (PSEN1) gene
ReproNeuro AD mutation (Cat. No.: RCDN002N)

  

Custom disease model cells on your request

We provide services making custom disease model cells on customer's request. This service includes acquisition of a patient sample, establishment of human iPS cells from the patient sample by RNA based reprogramming, and differentiation into functional cells (Cardiomyocytes, Hepatocytes and Neurons).
Please contact us for details.

ReproNeuro™ series media/reagents

Catalog No. Product Price
RCDN101 ReproNeuro Culture Medium

(Culture medium for extended culture of ReproNeuro™)

  • ReproNeuro Culture medium (40 mL)
  • ReproNeuro Additive (520 μL)
Contact us
RCDN102

ReproNeuro MQ Medium

(Culture and assay medium)

  • ReproNeuro MQ Medium(40 mL)
  • ReproNeuro Additive (520 μL)
Contact us
RCDN201

ReproNeuro Coat (150 μL)

(Coating Solution for ReproNeuro™)

Contact us

References

Publications

  • Odawara, Aoi, Masao Gotoh, and Ikuro Suzuki. “A three-dimensional neuronal culture technique that controls the direction of neurite elongation and the position of soma to mimic the layered structure of the brain.” RSC Adv. (2013).
  • Bottiglieri, Teodoro, et al. “Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.” The Journal of Neuroscience 32.27 (2012): 9173-9181.

Presentations

  • Society for Biomolecular Sciences(SBS), 14th AnnualConference & Exhibition 2008 (St. Louis), poster session, April 2008.
  • IBC Asia’s 4th Annual Stem Cells Asia Congress (Singapore), oral session, June 2008.
  • ELRIG and SBS Present: Drug Discovery (UK) poster session, September 2008.
  • Advances in Stem Cell Discoveries (San Francisco) oral session, September 2008.
  • Stem Cells: Drug Discovery and Therapeutics (London) oral session, February 2008.
  • Society for Biomolecular Science 15th Annual Conference (France), poster session, Best Poster 2009 Award-winning, April 2009.
  • Stem Cells and Regenerative Medicine Europe (UK), September 2009, Best Poster 2009 Award-winning.
  • MipTec Conference 2009, October 13-15, Basel Invited Lecture.
  • The 74th Annual Scientific Meeting of the Japanese Circulation Society(Kyoto), March 2010.
  • The 130th The Pharmaceutical Society of Japan(Okayama), March 2010.
  • The Society of Toxicology (SOT) 51st Annual Meeting (CA, USA), poster session, March 2012.
  • Safety Pharmacology Society (SPS), 13th annual meeting 2013 (Rotterdam, Netherlands), poster session, September 2013.
  • Automated Patch-Clamp systems and Ion Channel Expressing Cells 2013 (Tokyo), Verbal presentation 2013 Nov.
  • The 7th Takeda Science Foundation Symposium (Osaka), Poster presentation 2014 Jan.